206 related articles for article (PubMed ID: 32313141)
21. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.
Fernandes RC; Toubia J; Townley S; Hanson AR; Dredge BK; Pillman KA; Bert AG; Winter JM; Iggo R; Das R; Obinata D; ; Sandhu S; Risbridger GP; Taylor RA; Lawrence MG; Butler LM; Zoubeidi A; Gregory PA; Tilley WD; Hickey TE; Goodall GJ; Selth LA
Cell Rep; 2021 Jan; 34(1):108585. PubMed ID: 33406413
[TBL] [Abstract][Full Text] [Related]
22. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
23. YAP1 Is Involved in Tumorigenic Properties of Prostate Cancer Cells.
Collak FK; Demir U; Sagir F
Pathol Oncol Res; 2020 Apr; 26(2):867-876. PubMed ID: 30859486
[TBL] [Abstract][Full Text] [Related]
24. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells.
Machado-Neto JA; Lazarini M; Favaro P; Franchi GC; Nowill AE; Saad ST; Traina F
Exp Cell Res; 2014 Jun; 324(2):137-45. PubMed ID: 24726915
[TBL] [Abstract][Full Text] [Related]
25. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
Front Immunol; 2021; 12():622001. PubMed ID: 33737929
[TBL] [Abstract][Full Text] [Related]
26. ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.
Nguyen LT; Tretiakova MS; Silvis MR; Lucas J; Klezovitch O; Coleman I; Bolouri H; Kutyavin VI; Morrissey C; True LD; Nelson PS; Vasioukhin V
Cancer Cell; 2015 Jun; 27(6):797-808. PubMed ID: 26058078
[TBL] [Abstract][Full Text] [Related]
27. Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.
Matsuda Y; Narita S; Nara T; Mingguo H; Sato H; Koizumi A; Kanda S; Numakura K; Saito M; Inoue T; Hiroshima Y; Nanjo H; Satoh S; Tsuchiya N; Habuchi T
BMC Cancer; 2020 Apr; 20(1):302. PubMed ID: 32293349
[TBL] [Abstract][Full Text] [Related]
28. Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers.
Marx A; Schumann A; Höflmayer D; Bady E; Hube-Magg C; Möller K; Tsourlakis MC; Steurer S; Büscheck F; Eichenauer T; Clauditz TS; Graefen M; Simon R; Sauter G; Izbicki JR; Huland H; Heinzer H; Haese A; Schlomm T; Bernreuther C; Lebok P; Polonski A
Sci Rep; 2020 Jun; 10(1):8916. PubMed ID: 32488048
[TBL] [Abstract][Full Text] [Related]
29. Re: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.
Yang M; Li J; Li N; Guo H
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1212-1213. PubMed ID: 34035458
[No Abstract] [Full Text] [Related]
30. Neural Transcription Factors in Disease Progression.
Thaper D; Vahid S; Zoubeidi A
Adv Exp Med Biol; 2019; 1210():437-462. PubMed ID: 31900920
[TBL] [Abstract][Full Text] [Related]
31. Models of neuroendocrine prostate cancer.
Berman-Booty LD; Knudsen KE
Endocr Relat Cancer; 2015 Feb; 22(1):R33-49. PubMed ID: 25349195
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine differentiation of prostate cancer.
Li Z; Chen CJ; Wang JK; Hsia E; Li W; Squires J; Sun Y; Huang J
Asian J Androl; 2013 May; 15(3):328-32. PubMed ID: 23503426
[No Abstract] [Full Text] [Related]
33. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.
Park JW; Lee JK; Witte ON; Huang J
Mod Pathol; 2017 Sep; 30(9):1262-1272. PubMed ID: 28621319
[TBL] [Abstract][Full Text] [Related]
34. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
[TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
37. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance.
Chen WY; Wen YC; Lin SR; Yeh HL; Jiang KC; Chen WH; Lin YS; Zhang Q; Liew PL; Hsiao M; Huang J; Liu YN
Commun Biol; 2021 Jan; 4(1):22. PubMed ID: 33398073
[TBL] [Abstract][Full Text] [Related]
38. A fluorescence-coupled assay for gamma aminobutyric acid (GABA) reveals metabolic stress-induced modulation of GABA content in neuroendocrine cancer.
Ippolito JE; Piwnica-Worms D
PLoS One; 2014; 9(2):e88667. PubMed ID: 24551133
[TBL] [Abstract][Full Text] [Related]
39. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
Liu Q; Russell MR; Shahriari K; Jernigan DL; Lioni MI; Garcia FU; Fatatis A
Cancer Res; 2013 Jun; 73(11):3297-305. PubMed ID: 23536554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]